VITT相关抗PF4抗体不与SARS-CoV-2刺突蛋白交叉反应
疫苗诱导免疫性血栓性血小板减少症(VITT)由抗血小板因子4(PF4)抗体激活血小板所致。本研究通过计算机预测和实验验证,发现VITT患者纯化的抗PF4抗体不与SARS-CoV-2刺突蛋白交叉反应;在222例COVID-19患者中,8.6%检出抗PF4抗体,但仅4例显示弱至中度血小板活化,且无血栓并发症。结论表明疫苗接种诱导的抗PF4抗体不交叉识别刺突蛋白,VITT并非由针对刺突蛋白的免疫反应触发。
要点
- VITT患者抗PF4抗体不与SARS-CoV-2刺突蛋白交叉反应。
- COVID-19患者中8.6%存在抗PF4抗体,但血栓并发症与血小板活化无关。
- VITT的触发机制并非疫苗诱导的抗刺突蛋白免疫反应。
核心结论
- 疫苗接种诱导的抗PF4抗体不与SARS-CoV-2刺突蛋白交叉反应,表明针对刺突蛋白的免疫反应不是VITT的触发因素。
- 本研究中COVID-19患者检出的PF4反应性抗体与血栓并发症无关。
研究设计与样本
- 比较PF4与SARS-CoV-2刺突蛋白的免疫原性表位(计算机预测与3D建模),并检测VITT患者纯化的抗PF4抗体与重组刺突蛋白的反应性。
- 纳入14例VITT患者纯化的抗PF4抗体,以及来自5个欧洲中心的222例PCR确诊COVID-19患者血清,进行PF4-肝素ELISA和PF4依赖性血小板活化试验。
主要发现
- SARS-CoV-2刺突蛋白与PF4至少共享1个相似表位。
- 14例VITT患者的亲和纯化抗PF4抗体均不与SARS-CoV-2刺突蛋白交叉反应。
- 222例COVID-19患者中19例(8.6%)检出抗PF4抗体,仅4例显示弱至中度血小板活化,且无血栓并发症。
- 222例中10例(4.5%)发生COVID-19伴血栓形成,但均无PF4依赖性血小板活化抗体。
临床怎么用
- VITT的诊断与SARS-CoV-2刺突蛋白免疫反应无关,不应将刺突蛋白抗体作为VITT的替代标志物。
- COVID-19患者中抗PF4抗体阳性不必然提示血栓风险,需结合血小板活化试验判断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a severe adverse effect of ChAdOx1 nCoV-19 COVID-19 vaccine (Vaxzevria) and Janssen Ad26.COV2.S COVID-19 vaccine, and it is associated with unusual thrombosis. VITT is caused by anti-platelet factor 4 (PF4) antibodies activating platelets through their FcγRIIa receptors. Antibodies that activate platelets through FcγRIIa receptors have also been identified in patients with COVID-19. These findings raise concern that vaccination-induced antibodies against anti-SARS-CoV-2 spike protein cause thrombosis by cross-reacting with PF4. Immunogenic epitopes of PF4 and SARS-CoV-2 spike protein were compared using in silico prediction tools and 3D modeling. The SARS-CoV-2 spike protein and PF4 share at least 1 similar epitope. Reactivity of purified anti-PF4 antibodies from patients with VITT was tested against recombinant SARS-CoV-2 spike protein. However, none of the affinity-purified anti-PF4 antibodies from 14 patients with VITT cross-reacted with SARS-CoV-2 spike protein. Sera from 222 polymerase chain reaction-confirmed patients with COVID-19 from 5 European centers were tested by PF4-heparin enzyme-linked immunosorbent assays and PF4-dependent platelet activation assays. We found anti-PF4 antibodies in sera from 19 (8.6%) of 222 patients with COVID-19. However, only 4 showed weak to moderate platelet activation in the presence of PF4, and none of those patients developed thrombotic complications. Among 10 (4.5%) of 222 patients who had COVID-19 with thrombosis, none showed PF4-dependent platelet-activating antibodies. In conclusion, antibodies against PF4 induced by vaccination do not cross-react with the SARS-CoV-2 spike protein, indicating that the intended vaccine-induced immune response against SARS-CoV-2 spike protein is not the trigger of VITT. PF4-reactive antibodies found in patients with COVID-19 in this study were not associated with thrombotic complications.
引用
- Greinacher A, Selleng K, Mayerle J, et al. Anti-platelet factor 4 antibodies causing VITT do not cross-react with SARS-CoV-2 spike protein. Blood. 2021. PMID: 34280256. doi:10.1182/blood.2021012938
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。